சுற்றும் செல் இலவசம் மரபணு அட்லஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சுற்றும் செல் இலவசம் மரபணு அட்லஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சுற்றும் செல் இலவசம் மரபணு அட்லஸ் Today - Breaking & Trending Today

Is this the holy GRAIL for cancer detection?


Share
Last month a study funded by GRAIL as part of the Circulating Cell-free Genome Atlas (CCGA) reported validation results for GRAIL’s Galleri test. Galleri is a multi-cancer early detection test, a long sought after blood test that can reportedly screen for over 50 cancer types from a single blood draw.
Galleri works by detecting circulating tumour DNA (ctDNA) in the blood, a byproduct of the rapid turnover of tumour cells. Galleri as a product is now live and available in the USA for a list price of $949.
For a screening test such as Galleri, two metrics tell us almost everything we need to know about the performance of the test: specificity (true negative rate) and sensitivity (true positive rate). In the validation study, the authors screened 4077 people and reported sensitivity and specificity for each of the cancer types that Galleri can screen for. ....

United States , Circulating Cell Free Genome Atlas , ஒன்றுபட்டது மாநிலங்களில் , சுற்றும் செல் இலவசம் மரபணு அட்லஸ் ,

New blood test can accurately detect 50 types of cancer before symptoms emerge


New blood test can accurately detect 50 types of cancer before symptoms emerge
Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher risk of the disease, including patients aged 50 years or older, without symptoms.
In a paper published in the leading cancer journal
Annals of Oncologytoday (Friday), researchers report that the test accurately detected cancer, often before any symptoms arose, while having a very low false positive rate. The test also predicted where in the body the cancer is located with a high degree of accuracy, which could help doctors choose effective diagnostic tests. ....

France General , United States , United Kingdom , Fabrice Andr , Institut Gustave Roussy , Eric Klein , Emily Henderson , United Kingdom National Health Service , Grail Inc , Kidney Institute , Study First Author , Glickman Urological , Cleveland Clinic , Circulating Cell Free Genome Atlas , National Health Service , North America , Professor Fabrice Andr , பிரான்ஸ் ஜநரல் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , துணி அன்று , எரிக் க்ளீன் , எமிலி ஹென்டர்சன் , ஒன்றுபட்டது கிஂக்டம் தேசிய ஆரோக்கியம் சேவை , க்ரேல் இன்க் , கிட்நீ நிறுவனம் ,